These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

478 related items for PubMed ID: 16565261

  • 1. Associations between changes in hemoglobin and administered erythropoiesis-stimulating agent and survival in hemodialysis patients.
    Regidor DL, Kopple JD, Kovesdy CP, Kilpatrick RD, McAllister CJ, Aronovitz J, Greenland S, Kalantar-Zadeh K.
    J Am Soc Nephrol; 2006 Apr; 17(4):1181-91. PubMed ID: 16565261
    [Abstract] [Full Text] [Related]

  • 2. Anemia management and association of race with mortality and hospitalization in a large not-for-profit dialysis organization.
    Servilla KS, Singh AK, Hunt WC, Harford AM, Miskulin D, Meyer KB, Bedrick EJ, Rohrscheib MR, Tzamaloukas AH, Johnson HK, Zager PG.
    Am J Kidney Dis; 2009 Sep; 54(3):498-510. PubMed ID: 19628315
    [Abstract] [Full Text] [Related]

  • 3. Mortality in incident haemodialysis patients: time-dependent haemoglobin levels and erythropoiesis-stimulating agent dose are independent predictive factors in the ANSWER study.
    Fort J, Cuevas X, García F, Pérez-García R, Lladós F, Lozano J, Martín-Malo A, ANSWER study.
    Nephrol Dial Transplant; 2010 Aug; 25(8):2702-10. PubMed ID: 20176608
    [Abstract] [Full Text] [Related]

  • 4. Challenging the validity of the EPO index.
    Kaysen GA, Müller HG, Ding J, Chertow GM.
    Am J Kidney Dis; 2006 Jan; 47(1):166. PubMed ID: 16377397
    [Abstract] [Full Text] [Related]

  • 5. Epoetin alfa use in patients with ESRD: an analysis of recent US prescribing patterns and hemoglobin outcomes.
    Collins AJ, Brenner RM, Ofman JJ, Chi EM, Stuccio-White N, Krishnan M, Solid C, Ofsthun NJ, Lazarus JM.
    Am J Kidney Dis; 2005 Sep; 46(3):481-8. PubMed ID: 16129210
    [Abstract] [Full Text] [Related]

  • 6. Changes in hemoglobin level distribution in US dialysis patients from June 2006 to November 2008.
    Spiegel DM, Khan I, Krishnan M, Mayne TJ.
    Am J Kidney Dis; 2010 Jan; 55(1):113-20. PubMed ID: 19932539
    [Abstract] [Full Text] [Related]

  • 7. Association of mean weekly epoetin alfa dose with mortality risk in a retrospective cohort study of Medicare hemodialysis patients.
    Weinhandl ED, Gilbertson DT, Collins AJ.
    Am J Nephrol; 2011 Jan; 34(4):298-308. PubMed ID: 21829009
    [Abstract] [Full Text] [Related]

  • 8. Association of morbid obesity and weight change over time with cardiovascular survival in hemodialysis population.
    Kalantar-Zadeh K, Kopple JD, Kilpatrick RD, McAllister CJ, Shinaberger CS, Gjertson DW, Greenland S.
    Am J Kidney Dis; 2005 Sep; 46(3):489-500. PubMed ID: 16129211
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Hemoglobin level, chronic kidney disease, and the risks of death and hospitalization in adults with chronic heart failure: the Anemia in Chronic Heart Failure: Outcomes and Resource Utilization (ANCHOR) Study.
    Go AS, Yang J, Ackerson LM, Lepper K, Robbins S, Massie BM, Shlipak MG.
    Circulation; 2006 Jun 13; 113(23):2713-23. PubMed ID: 16754803
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Population pharmacokinetic/pharmacodynamic model for C.E.R.A. in both ESA-naive and ESA-treated chronic kidney disease patients with renal anemia.
    Chanu P, Gieschke R, Charoin JE, Pannier A, Reigner B.
    J Clin Pharmacol; 2010 May 13; 50(5):507-20. PubMed ID: 20179322
    [Abstract] [Full Text] [Related]

  • 14. It's time to compare anemia management strategies in hemodialysis.
    Coyne DW.
    Clin J Am Soc Nephrol; 2010 Apr 13; 5(4):740-2. PubMed ID: 20299363
    [Abstract] [Full Text] [Related]

  • 15. [Regarding the optimal hemoglobin target range in renal anemia].
    Maurin N.
    Med Klin (Munich); 2008 Sep 15; 103(9):633-7. PubMed ID: 18813886
    [Abstract] [Full Text] [Related]

  • 16. Atorvastatin increases erythropoietin-stimulating agent hyporesponsiveness in maintenance hemodialysis patients: role of anti-inflammation effects.
    Chiang CK, Yang SY, Peng YS, Hsu SP, Pai MF, Huang JW, Hung KY, Wu KD.
    Am J Nephrol; 2009 Sep 15; 29(5):392-7. PubMed ID: 18974640
    [Abstract] [Full Text] [Related]

  • 17. Effect of variability in anemia management on hemoglobin outcomes in ESRD.
    Lacson E, Ofsthun N, Lazarus JM.
    Am J Kidney Dis; 2003 Jan 15; 41(1):111-24. PubMed ID: 12500228
    [Abstract] [Full Text] [Related]

  • 18. Iron-replete hemodialysis patients do not require higher EPO dosages when converting from subcutaneous to intravenous administration: results of the Italian Study on Erythropoietin Converting (ISEC).
    Pizzarelli F, David S, Sala P, Icardi A, Casani A.
    Am J Kidney Dis; 2006 Jun 15; 47(6):1027-35. PubMed ID: 16731298
    [Abstract] [Full Text] [Related]

  • 19. Exceeding hemoglobin target levels in US hemodialysis patients receiving epoetin, 1999 to 2002.
    Foley RN, Zhang R, Gilbertson DT, Dunning S, Ishani A, Collins AJ.
    Hemodial Int; 2007 Jul 15; 11(3):333-9. PubMed ID: 17576299
    [Abstract] [Full Text] [Related]

  • 20. The controversy surrounding hemoglobin and erythropoiesis-stimulating agents: what should we do now?
    Singh AK.
    Am J Kidney Dis; 2008 Dec 15; 52(6 Suppl):S5-13. PubMed ID: 19010260
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.